Literature DB >> 11927260

GnRH binding RNA and DNA Spiegelmers: a novel approach toward GnRH antagonism.

Susanne Leva1, Andrea Lichte, Jens Burmeister, Peter Muhn, Birgit Jahnke, Dirk Fesser, Jeannette Erfurth, Petra Burgstaller, Sven Klussmann.   

Abstract

Mirror-image oligonucleotide ligands (Spiegelmers) that bind to the pharmacologically relevant target gonadotropin-releasing hormone I (GnRH) with high affinity and high specificity have been identified using the Spiegelmer technology. GnRH is a decapeptide that plays an important role in mammalian reproduction and sexual maturation and is associated with several benign and malignant diseases. First, aptamers that bind to D-GnRH with dissociation constants of 50-100 nM were isolated out of RNA and DNA libraries. The respective enantiomers of the DNA and RNA aptamers were synthesized, and their binding to L-GnRH was shown. These Spiegelmers bind to L-GnRH with similar affinity to that of the corresponding aptamers that bind to D-GnRH. We further demonstrated dose-dependent inhibition of GnRH-induced Ca(2+) release in Chinese hamster ovary cells that were stably transfected with the human GnRH receptor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927260     DOI: 10.1016/s1074-5521(02)00111-4

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  27 in total

1.  Inhibition of stimulated meningeal blood flow by a calcitonin gene-related peptide binding mirror-image RNA oligonucleotide.

Authors:  Thomas Denekas; Markus Tröltzsch; Axel Vater; Sven Klussmann; Karl Messlinger
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

2.  Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX.

Authors:  Axel Vater; Florian Jarosch; Klaus Buchner; Sven Klussmann
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

Review 3.  RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy.

Authors:  Peixuan Guo
Journal:  J Nanosci Nanotechnol       Date:  2005-12

4.  In vivo biodistribution and pharmacokinetics of 18F-labelled Spiegelmers: a new class of oligonucleotidic radiopharmaceuticals.

Authors:  Raphaël Boisgard; Bertrand Kuhnast; Stefan Vonhoff; Chéraz Younes; Françoise Hinnen; Jean-Marc Verbavatz; Bernard Rousseau; Jens Peter Fürste; Britta Wlotzka; Frédéric Dollé; Sven Klussmann; Bertrand Tavitian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12-22       Impact factor: 9.236

5.  A DNA Spiegelmer to staphylococcal enterotoxin B.

Authors:  Werner G Purschke; Falko Radtke; Frank Kleinjung; Sven Klussmann
Journal:  Nucleic Acids Res       Date:  2003-06-15       Impact factor: 16.971

Review 6.  Aptamers as a novel tool for diagnostics and therapy.

Authors:  Onat Kadioglu; Anna Helena Malczyk; Henry Johannes Greten; Thomas Efferth
Journal:  Invest New Drugs       Date:  2015-02-01       Impact factor: 3.850

7.  Anti-ghrelin Spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats.

Authors:  P Kobelt; S Helmling; A Stengel; B Wlotzka; V Andresen; B F Klapp; B Wiedenmann; S Klussmann; H Mönnikes
Journal:  Gut       Date:  2005-06-30       Impact factor: 23.059

8.  The expanding view of RNA and DNA function.

Authors:  Ronald R Breaker; Gerald F Joyce
Journal:  Chem Biol       Date:  2014-09-18

9.  Biostable aptamers with antagonistic properties to the neuropeptide nociceptin/orphanin FQ.

Authors:  Dirk Faulhammer; Bernd Eschgfäller; Sandra Stark; Petra Burgstaller; Werner Englberger; Jeannette Erfurth; Frank Kleinjung; Johanna Rupp; Sebastian Dan Vulcu; Werner Schröder; Stefan Vonhoff; Hermann Nawrath; Clemens Gillen; Sven Klussmann
Journal:  RNA       Date:  2004-03       Impact factor: 4.942

10.  In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class.

Authors:  Britta Wlotzka; Susanne Leva; Bernd Eschgfäller; Jens Burmeister; Frank Kleinjung; Christine Kaduk; Peter Muhn; Holger Hess-Stumpp; Sven Klussmann
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.